InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Renee PremiumMember
09/25/19 9:30 AM
profile icon
BrianSkidless Free
08/29/19 6:09 PM
profile icon
echi8 Free
02/18/19 8:05 PM
profile icon
Renee PremiumMember
12/04/18 5:09 PM
profile icon
Green_power Free
10/04/18 2:27 PM
profile icon
Green_power Free
10/03/18 12:21 PM
profile icon
EM60192 Free
10/03/18 8:58 AM
profile icon
Green_power Free
09/27/18 8:31 AM
profile icon
ORCA PremiumMember
06/06/18 4:41 PM
profile icon
declaes Free
06/06/18 3:18 PM
profile icon
ORCA PremiumMember
05/24/18 2:19 PM
profile icon
ferndale2000 Free
05/24/18 12:30 PM
profile icon
ORCA PremiumMember
04/30/18 12:34 PM
profile icon
plinter1 Free
04/30/18 12:25 PM
profile icon
ORCA PremiumMember
04/25/18 10:29 AM
profile icon
jpowellvlc Free
04/25/18 2:54 AM
profile icon
TenKay Free
04/24/18 5:46 PM
profile icon
plinter1 Free
04/24/18 8:49 AM
profile icon
ORCA PremiumMember
04/20/18 10:03 AM
profile icon
echi8 Free
04/19/18 7:45 PM
profile icon
declaes Free
04/19/18 4:26 PM
profile icon
TheShadow Free
04/19/18 4:21 PM
profile icon
Klinsmann PremiumMember
04/19/18 12:30 PM
profile icon
declaes Free
04/19/18 11:46 AM
profile icon
nokomis Free
04/19/18 11:34 AM
profile icon
stockman89 Free
04/19/18 10:53 AM
profile icon
grich1 Free
04/19/18 10:48 AM
profile icon
grich1 Free
04/19/18 10:37 AM
profile icon
jpowellvlc Free
04/19/18 10:28 AM
profile icon
grich1 Free
04/19/18 10:16 AM
profile icon
R2DT Free
04/19/18 10:10 AM
profile icon
Dr mac Free
04/19/18 10:03 AM
profile icon
finesand Free
04/19/18 9:42 AM
profile icon
jonnyvs Free
04/19/18 8:32 AM
profile icon
Klinsmann PremiumMember
04/19/18 7:44 AM
profile icon
jonnyvs Free
04/19/18 7:02 AM
profile icon
Klinsmann PremiumMember
04/19/18 6:10 AM
profile icon
Klinsmann PremiumMember
04/19/18 4:42 AM
profile icon
declaes Free
04/19/18 4:22 AM

Argos Therapeutics Inc fka ARGSQ RSS Feed

Followers
55
Posters
209
Posts (Today)
0
Posts (Total)
1990
Created
06/28/14
Type
Free
Moderators
Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its products include AGS-003, which is under Phase III clinical trials and intended for the treatment of metastatic renal cell carcinoma (clear cell); and AGS-004, which is under Phase IIb clinical trials and is intended for the treatment of Human Immunodeficiency Virus. The company also develops AGS-003 for metastatic renal cell carcinoma (non-clear cell), early stage RCC, and other solid tumors. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.(yahoo)
 

Recent Timeline

- Feb '17 DMC Recommends Discontinuation of AGS-003 ADAPT Trial
- March '17 Communicated BK risk
- April '18 AGS-003 ADAPT Trial Perspective to Continue Trial
- May '17 FDA Agrees on AGS-003 ADAPT Continuation and will Review Protocol Amendment
- June '17 $5M funding round - BK risk removed, company continues
- July '17 AGS-004 Open-Label Ph1 HIV Trial Reaches PE, 6 pt, 2-fold increase
- Sep '17 AGS-004 Phase 2 HIV eradication trial : Dosing First Patient
- Sep '17 AGS-003 ADAPT Trial Interim Data Discussion @ ESMO
- Nov '17 Lummy made a $1.5M milestone payment
- Dec '17 CC Transcript
- Jan '18 Lummy's $1.5M 0.375M shares @ $4/sh equity investment, to be closed & converted on 2018-03-07
- Jan '18 RS 1:20
- Feb '18 424B5 of $200M Shelf 333-215480: $15M Equity Sales via Cowen, ATM
- Feb '18 Option to license PD1 Checkpoint Inhibitors for other/more drug variants (?)
- Feb '18 Received a patent for AGS-004 production, their HIV drug

Upcoming Catalysts

- Early 2018 AGS-004 Pilot Trial 12 patients, primary completion March 2018. Positive data from 6 patients published.Current EV 2018-03-16 8-K

Goes on OTCQB on 4/23 '18

Board Info
Posts Today
0
Posts (Total)
1990
Posters
209
Moderators
New Post